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Abstract
Introduction Vitamin D receptor (VDR) polymorphisms have
been inconsistently associated with breast cancer risk. Whether
risk is influenced by polymorphisms in other vitamin D
metabolism genes and whether calcium or vitamin D intake
modifies risk by genotype have not been evaluated.
Methods We conducted a nested case-control study within the
Cancer Prevention Study II Nutrition Cohort of associations
between breast cancer and four VDR single-nucleotide
polymorphisms (SNPs), Bsm1,Apa1,Taq1, and Fok1, a poly(A)
microsatellite, and associated haplotypes (baTL and BAtS). We
also examined one SNP in the 24-hydroxylase gene (CYP24A1)
and two in the vitamin D-binding protein (group-specific
component [GC]) gene. Participants completed a questionnaire
on diet and medical history at baseline in 1992. This study
includes 500 postmenopausal breast cancer cases and 500
controls matched by age, race/ethnicity, and date of blood
collection.
Results Incident breast cancer was not associated with any
genotype examined. However, women with the Bsm1 bb SNP
who consumed greater than the median intake of total calcium
(≥902 mg/day) had lower odds of breast cancer compared to
women with the Bb or BB genotype and less than the median
calcium intake (odds ratio 0.61, 95% confidence interval 0.38 to
0.96; pinteraction = 0.01). Similar interactions were observed for
Taq1 (T allele) and the poly(A) (LL) repeat.
Conclusion We found no overall association between selected
vitamin D pathway genes and postmenopausal breast cancer
risk. However, certain VDR gene polymorphisms were
associated with lower risk in women consuming high levels of
calcium, suggesting that dietary factors may modify associations
by VDR genotype.
Introduction
Vitamin D has been associated with a lower risk of several
types of cancer, including breast cancer [1,2]. Its action is
mediated through the vitamin D receptor (VDR), a nuclear tran-
scription-regulating factor that signals the synthesis of pro-
teins involved in bone mineral homeostasis and cell-cycle
regulation [2]. The receptor is present in most cell types,
including normal and neoplastic breast tissue [3]. Clinically,
breast tumors with greater VDR expression relapse more
slowly after first diagnosis [4].
The VDR gene contains several polymorphisms. Three single-
nucleotide polymorphisms (SNPs) located near the 3' region
have been examined in relation to breast cancer [2]. These pol-
ymorphisms, identified by their restriction endonuclease cleav-
age sites (Taq1,Bsm1, and Apa1), include an intronic G→A
replacement (Bsm1, rs1544410, G = b), an intronic C→A
replacement (Apa1, rs7975232, C = a), and a T→C replace-
ment in exon 9 (Taq1, rs731236, C = t), which result in a syn-
onymous change at codon 352. Although not functional, these
SNPs are strongly linked with a poly(A) microsatellite repeat in
the 3' untranslated region [5,6] which may influence VDR
mRNA stability. Five [7-11] of nine [7-15] studies reported
higher breast cancer risk associated with the Bsm1 bb geno-
CI = confidence interval; CPS = Cancer Prevention Study; DBP = vitamin D-binding protein; FFQ = food frequency questionnaire; GC = group-
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type. Other VDR 3' SNPs or haplotypes have been inconsist-
ently related to breast cancer [16].
The presence of the Fok1 f allele in the 5' promoter region of
the VDR (rs2228570) results in production of a VDR protein
that is three amino acids longer and less effective as a tran-
scriptional activator [16]. The ff genotype was associated with
a statistically significant 34% higher breast cancer risk in the
Nurses' Health Study [15]. Previous smaller studies of Fok1
and breast cancer risk were null [7,13,17].
Gene-environment interactions may explain in part the incon-
sistencies in the association between VDR SNPs and breast
cancer across studies. Dietary factors are known to impact the
vitamin D endocrine system [18], and recent studies suggest
that diet may also influence autocrine/paracrine vitamin D
metabolism [19]. Few studies have examined interactions
between dietary factors and VDR polymorphisms in relation to
breast cancer risk. Furthermore, polymorphisms in other genes
in the vitamin D metabolic pathway have not been examined in
relation to breast cancer risk.
We examined several polymorphisms in the VDR gene, their
associated haplotypes, and polymorphisms in the vitamin D-
binding (group-specific component [GC]) protein and
1,25(OH)2D degradation enzyme (CYP24A1) genes in rela-
tion to breast cancer risk in a nested case-control study of
postmenopausal women enrolled in a large prospective
cohort. Of particular a priori interest was whether calcium and
vitamin D intakes modified associations by genotype.
Materials and methods
Study population
Women in this analysis were participants in the Cancer Pre-
vention Study (CPS) II Nutrition Cohort, a prospective study of
cancer incidence among men and women from 21 states in
the US, established by the American Cancer Society in 1992
[20]. At enrollment, 86,404 men and 97,788 women com-
pleted a 10-page, self-administered questionnaire on medical,
dietary, reproductive, and lifestyle variables. Beginning in
1997, follow-up questionnaires were sent to cohort members
every 2 years to update exposure information and to ascertain
newly diagnosed tumors.
From June 1998 through June 2001, blood specimens were
collected from 21,965 Nutrition Cohort postmenopausal
women. Using blood samples, we identified 502 breast cancer
cases who were cancer-free in 1992. For each case, we ran-
domly selected one postmenopausal female control who had
provided a blood sample and was cancer-free (except non-
melanoma skin cancer) at the time of the case's diagnosis
[21]. Controls were individually matched to cases on birth
date (± 6 months), race/ethnicity (Caucasian, African-Ameri-
can, Hispanic, Asian, other/unknown), and date of blood col-
lection (± 6 months) using risk-set sampling. After excluding 2
cases with no match, 500 cases and 500 controls were avail-
able for analysis. All aspects of the CPS II cohort were
approved by the Emory University (Atlanta, GA, USA) Institu-
tional Review Board.
Laboratory methods
Genotyping was performed at Applied Biosystems (ABI, Fos-
ter City, CA, USA) by laboratory personnel blinded to case-
control status; blinded quality control samples for 10% of par-
ticipants were inserted to validate genotyping procedures.
TaqMan (ABI, Foster City, CA, USA) was used to distinguish
alleles of the VDR gene at restriction enzyme sites Fok1,
Bsm1, Apa1, and Taq1. A variable-length poly(A) sequence in
the 3' untranslated region was assessed using methods previ-
ously described [6] and was classified as short (S, A14-A17) or
long (L, A18-A22).
We also genotyped selected SNPs in vitamin D pathway
genes that were relatively common and validated at study
inception. Using TaqMan, we genotyped a T432G aspartate
to glutamate SNP (rs7041) and an A436C threonine to lysine
SNP (rs4588), both in exon 11 of the GC gene, which codes
for the vitamin D-binding protein (DBP). We also measured a
synonymous A→G  S N P  i n  ex o n 4  of  t he  CYP24A1  gene
(rs2296241), which encodes 24(OH)ase, which initiates deg-
radation of 1,25(OH)2D.
Concordance for quality control samples was 100%. The
overall success rate for genotyping assays was at least 95%,
except for Bsm1 (93%). All SNPs were in Hardy-Weinberg
equilibrium (p >0.05).
Dietary assessment
Calcium, vitamin D, and dairy product intakes were measured
in 1992 to 1993 [20] using a semi-quantitative 68-item food
frequency questionnaire (FFQ), which is a modification of the
brief 'Health Habits and History Questionnaire' developed by
Block and colleagues [22]. Dietary and total nutrient intakes
were estimated using the Diet Analysis System version 3.8a
(Division of Cancer Prevention and Control, National Cancer
Institute, Bethesda, MD, USA) [23]. Total calcium estimates
(mg/day) included contributions from diet, individual calcium
supplements (250, 500, 600, or 750 mg per tablet), and mul-
tivitamin pills (estimated at 130 mg per multivitamin pill). Vita-
min D values were added to the nutrient database using US
Department of Agriculture sources [24]. Total intake of vitamin
D (IU/day) was estimated from diet (fortified milk, cereals, and
fish) and multivitamin usage (400 IU per pill). Nutrient esti-
mates were adjusted for total energy using the residual
method [25].
The FFQ was validated using four random 24-hour recalls col-
lected throughout a 1-year period as the comparison measure
among 441 Nutrition Cohort participants [26]. Median energy-
adjusted, attenuation-corrected Pearson validity correlationsAvailable online http://breast-cancer-research.com/content/9/1/R9
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and 95% confidence intervals (CIs) among women were high
for dietary calcium (r = 0.66, 95% CI 0.51 to 0.76) and for
dairy products (r = 0.63, 95% CI 0.45 to 0.77).
Statistical analyses
We used a χ2  test to assess whether VDR, GC, and
CYP24A1 genotype distributions were in Hardy-Weinberg
equilibrium. Haplotypes of the VDR SNPs Bsm1,Apa1, and
Taq1 and the poly(A) repeat were estimated using the expec-
tation-maximization algorithm implemented in the TAGSNPS
program [27]. To account for matching, conditional logistic
regression was used to examine the association between all
SNPs and the VDR haplotypes and postmenopausal breast
cancer risk. We adjusted for additional risk factors and con-
founders as noted below. The main analysis combined invasive
(n = 393) and in situ (n = 107) breast tumors; sensitivity anal-
yses excluding in situ cases showed similar findings; thus, all
cases are presented.
Covariates included education, age at menopause and
menarche, parity, age at first live birth, personal history of
benign breast disease, family history of breast cancer in
mother or sisters, postmenopausal hormone replacement ther-
apy use, and body mass index. Adjustment for alcohol con-
sumption did not change the effect estimates and was not
included.
We examined whether dietary or total calcium or vitamin D
modified associations by genotype; interaction terms between
genotypes and each dietary variable in continuous form were
included in the conditional logistic regression models. Total
energy intake was included in the models examining dietary
interactions. Two-way interactions of the VDR haplotypes,
Fok1, GC SNPs and the CYP24A1 SNP were examined. Sta-
tistical interaction was evaluated using the Wald test; a p value
of less than 0.05 was considered statistically significant.
Results
Descriptive characteristics of participants in this study are pre-
sented in Table 1. Cases and controls had a median age of 62
years (range 43 to 75 years) at enrollment in 1992, and 99%
were Caucasian. None of the VDR genotypes or polymor-
phisms in the vitamin D-binding (GC) or CYP24A1 gene was
significantly associated with overall postmenopausal breast
cancer risk (Table 2). Heterozygote and homozygote variants
for SNPs near the 3' end of the VDR gene were combined
because of similar odds ratios (ORs). Three VDR haplotypes
were identified that explained more than 96% of the variance
among these SNPs: baTL (45.2%), BAtS (38.7%), and bATL
(12.3%). Haplotype associations were similarly null: baTL OR
= 0.89 (95% CI 0.66 to 1.20), BAtS OR = 1.24 (95% CI 0.92
to 1.66), and bATL OR = 0.96 (95% CI 0.69 to 1.32) for one
or two copies vers
In analyses stratified by dietary factors, total calcium intake
(but not vitamin D intake) modified the associations between
polymorphisms near the 3' end of the VDR and breast cancer
risk (Table 3us none.). Compared to women with less than
median total calcium intakes (<902 mg/day) and the BB or Bb
Bsm1  genotype (reference group), women with calcium
intakes of more than 902 mg/day and the bb genotype had a
39% lower risk of breast cancer (pinteraction = 0.01). Similar
findings were observed for those with the Taq1 TT and the
poly(A) LL tail. These interactions were similar and statistically
significant for dietary calcium, and no effect modification was
observed with dietary vitamin D or dairy product consumption.
Diet did not modify the associations between GC  or
CYP24A1 gene polymorphisms and breast cancer risk (not
Table 1
Selected characteristics of breast cancer cases and controls
Variable Cases n = 500 Controls n = 500
Mean ± standard deviation
Age at baseline (years) 61.9 ± 6.0 61.9 ± 6.0
Age at menarche (years) 12.7 ± 1.4 12.6 ± 1.4
Age at menopause (years) 48.5 ± 6.4 48.1 ± 6.0
Paritya 3.0 ± 1.2 3.3 ± 1.5
Race Percentage
White 98.6 98.8
Other or missing 1.4 1.2
History of breast cyst 38.8 30.0
Family history of breast cancer 20.2 15.0
Ever pregnant 88.8 90.0
aMean number of children only among parous women.Breast Cancer Research    Vol 9 No 1    McCullough et al.
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shown). We also observed no statistically significant effect
modification in analyses stratified by median UV index for the
state of residence as a proxy for cutaneous production of vita-
min D. In addition, we observed no significant interactions
between any two-way combination of VDR haplotypes, Fok1,
or CYP24A1 or GC genotypes or in specific combinations of
Fok1 and poly(A) genotypes.
Discussion
None of the genotypes or haplotypes examined from the vita-
min D pathway was associated with postmenopausal breast
cancer risk in all women. However, women with a calcium
intake higher than the median were at lower breast cancer risk
if they had the VDR Bsm1 bb, Taq1 TT, or the poly(A) long
repeat (LL) genotype. Among women with a calcium intake
Table 2
Associations between SNPs in VDR, GC, and CYP24A1 genes and postmenopausal breast cancer riska
Frequency Matched only Multivariate-adjustedb
SNP Cases Controls (%) OR 95% CI OR 95% CI
VDR
Fok1 (rs2228570)
FF 191 185 (37.0) 1.00 - 1.00 -
Ff 207 227 (45.4) 0.89 (0.68–1.17) 0.78 (0.58–1.05)
ff 77 68 (13.6) 1.11 (0.75–1.63) 0.98 (0.65–1.50)
Taq1 (rs731236)
tt or Tt 336 312 (62.4) 1.00 - 1.00 -
TT 158 180 (36.0) 0.82 (0.63–1.06) 0.83 (0.62–1.12)
Apa1 (rs7975232)
AA 147 129 (25.8) 1.00 - 1.00 -
Aa or aa 341 348 (69.6) 0.87 (0.65–1.15) 0.87 (0.64–1.18)
Bsm1 (rs1544410)
BB or Bb 321 290 (58.0) 1.00 - 1.00 -
bb 151 170 (34.0) 0.81 (0.61–1.06) 0.84 (0.62–1.15)
Poly(A) tail
SS or SL 328 304 (60.8) 1.00 - 1.00 -
LL 158 177 (35.4) 0.83 (0.63–1.08) 0.83 (0.61–1.12)
GC protein (rs4588)
C/C 240 246 (51.7) 1.00 - 1.00 -
A/C 202 186 (39.1) 1.11 (0.84–1.45) 1.11 (0.82–1.48)
A/A 48 44 (9.2) 1.13 (0.73–1.76) 1.30 (0.80–2.13)
GC protein (rs7041)
G/G 154 149 (30.4) 1.00 - 1.00 -
G/T 237 235 (48.0) 0.98 (0.72–1.33) 0.94 (0.67–1.31)
T/T 103 106 (21.6) 0.94 (0.66–1.33) 0.96 (0.65–1.41)
CYP24A1 (rs2296241)
A/A 141 139 (28.4) 1.00 - 1.00 -
A/G 254 253 (51.6) 0.99 (0.74–1.31) 1.03 (0.75–1.41)
G/G 99 98 (20.0) 1.00 (0.70–1.43) 1.05 (0.71–1.56)
aAll models contain a variable for unknown SNP genotype which is not presented. bModels are adjusted for body mass index, history of breast 
cyst, hormone replacement therapy use, family history of breast cancer, education, parity and age at first birth combined, age at menarche, and 
age at menopause. CI, confidence interval; GC, group-specific component; OR, odds ratio; SNP, single-nucleotide polymorphism; VDR, vitamin D 
receptor.Available online http://breast-cancer-research.com/content/9/1/R9
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lower than the median, these VDR genotypes were not asso-
ciated with lower breast cancer risk.
The lack of association between the Bsm1 bb genotype or
associated polymorphisms in the 3' region and breast cancer
risk is in contrast to findings in five studies that reported
increased risk of breast cancer, mostly among Caucasian
women with the bb genotype [7-11]. Four other studies, plus
ours, have not replicated this association [12-15]; two of these
were in Hispanic [13] and Taiwanese [14] women. Other
SNPs in the baT haplotype allele likewise have been inconsist-
ently related to breast cancer risk [16]. It is unclear whether
chance or underlying differences in the populations studied
explain these inconsistencies. It is conceivable that differ-
ences in background risk factor profiles (menopausal status,
reproductive factors, obesity, or dietary intake) contribute to
these variations. Most of these studies included both pre- and
postmenopausal cases; in the one study that presented
results stratified by menopausal status [15], results for the
BsmI BB versus the bb allele were similar for premenopausal
(OR = 0.92) and postmenopausal (OR = 0.94) women.
In our study, dietary calcium intake, but not vitamin D intake,
significantly modified the association between VDR SNPs
near the 3' end of the gene and breast cancer risk. Both
nutrients have direct effects on cell proliferation and differenti-
ation of several cancer cell lines in vitro [28,29]. In a rodent
model, calcium reduces fat-induced cell proliferation by main-
taining intracellular calcium concentrations [30]. It is plausible
that polymorphisms in the VDR gene could modify the effects
of exposures such as vitamin D or calcium on breast cancer
risk, although the specific mechanisms in humans are
unknown. Although vitamin D intake did not modify risk in our
analysis, we did not measure plasma 25(OH)D, an integrated
Table 3
VDR genotype and postmenopausal breast cancer risk stratified by total calcium and vitamin D intakesa
Total calcium (mg/day) Total vitamin D (IU/day)
<902 902+ <222 222+
SNP OR 95% CI OR 95% CI OR 95% CI OR 95% CI
Fok 1
FF 1.00 - 0.91 (0.56–1.47) 1.00 - 0.89 (0.55–1.45)
Ff 0.79 (0.50–1.25) 0.80 (0.50–1.26) 0.72 (0.45–1.14) 0.88 (0.56–1.39)
ff 1.08 (0.56–2.09) 0.63 (0.32–1.24) 1.03 (0.53–1.99) 0.68 (0.36–1.29)
pinteraction = 0.34b pinteraction = 0.18
Taq1
tt or Tt 1.00 - 1.16 (0.81–1.65) 1.00 - 1.02 (0.70–1.49)
TT 1.24 (0.79–1.94) 0.64 (0.41–0.99) 0.88 (0.56–1.38) 0.77 (0.50–1.21)
pinteraction = 0.01 pinteraction = 0.36
Apa1
AA 1.00 - 0.86 (0.49–1.50) 1.00 - 0.86 (0.48–1.53)
Aa or aa 0.86 (0.53–1.38) 0.74 (0.47–1.17) 0.77 (0.49–1.20) 0.82 (0.52–1.31)
pinteraction = 0.77 pinteraction = 0.47
Bsm1
BB or Bb 1.00 - 1.05 (0.71–1.55) 1.00 - 0.90 (0.60–1.35)
bb 1.20 (0.73–1.95) 0.61 (0.38–0.96) 0.72 (0.44–1.18) 0.78 (0.49–1.26)
pinteraction = 0.01 pinteraction = 0.90
Poly(A) tail
SS or SL 1.00 - 1.16 (0.81–1.67) 1.00 - 0.96 (0.66–1.41)
LL 1.18 (0.74–1.87) 0.66 (0.42–1.04) 0.79 (0.50–1.26) 0.77 (0.49–1.21)
pinteraction = 0.02 pinteraction = 0.72
aMultivariate adjusted models contain the SNP, dietary exposure, and interaction term and adjust for body mass index, history of breast cyst, 
hormone replacement therapy use, family history of breast cancer, education, parity and age at first birth combined, age at menarche, age at 
menopause, and total energy intake. bInteraction terms were created using continuous form of dietary variables. CI, confidence interval; OR, odds 
ratio; SNP, single-nucleotide polymorphism; VDR, vitamin D receptor.Breast Cancer Research    Vol 9 No 1    McCullough et al.
Page 6 of 7
(page number not for citation purposes)
measure of vitamin D status from diet and UVB synthesis.
Higher circulating levels of the storage form of vitamin D
(25(OH)D) may lower breast cancer risk [9,31], potentially by
providing substrate for breast tissue-specific synthesis of
1,25(OH)2D [3]. In one case-control study in the UK, women
with low plasma 25(OH)D levels and the BsmI bb VDR geno-
type had a 6.8-fold higher risk of breast cancer than individuals
with higher 25(OH)D levels and the BB or Bb genotype [9].
Thus, calcium or related nutrients may influence tissue-spe-
cific vitamin D metabolism in ways that are as yet unclear, pos-
sibly varying by VDR genotype. The interactions we observed
may also be due to chance and should be replicated.
Our null findings for the Fok1 ff SNP and breast cancer risk do
not replicate the positive association observed in the Nurses'
Health Study [15] but do agree with those of three smaller
studies [7,13,17], nor did we replicate previously reported
potential interactions between different VDR polymorphisms
observed by others [8,15]. Guy and colleagues [8] reported
an approximately two-fold increase in risk among women with
the FFLL or FfLL genotypes versus other combinations;
among patients with metastases, the risk was three-fold
greater. The mix of grade, lymph node involvement, or metas-
tases in cases studied may also contribute to variability in find-
ings across studies.
We observed no association with two non-synonymous poly-
morphisms in the GC  gene (codes for DBP) or one in
CYP24A1 and postmenopausal breast cancer. The polymor-
phic DBP facilitates vitamin D actions, and DBP alleles differ
in their affinity for 1,25(OH)2 D [32]. The CYP24A1  gene
codes for 24(OH)ase, which degrades 1,25(OH)2D. The
potential for the SNPs we examined to alter DBP or CYP24A1
function is possible but has not been studied. Some studies
have suggested a relationship of these SNPs with other out-
comes, including asthma, glucose tolerance, and bone mineral
density [33-35]. We are not aware of any studies that exam-
ined these SNPs in relation to breast cancer.
Limitations of this analysis include the use of a single assess-
ment of diet, on average 6 years before diagnosis of breast
cancer, which may have led to misclassification of dietary
intake. We did not measure blood levels of 25(OH)D to
assess vitamin D status. However, our FFQ was validated [26]
and diet was assessed before cancer diagnosis. Larger case
numbers would have provided greater statistical power to
examine gene-gene and gene-diet interactions; however, this
study is among the largest published to date for postmenopau-
sal breast cancer.
Conclusion
Our research does not support an independent association
between selected polymorphisms in the VDR, GC, or
CYP24A1  genes and postmenopausal breast cancer risk
among US Caucasian women. However, calcium intake
appeared to modify the association of VDR SNPs with breast
cancer risk. More research is needed to determine whether
environmental factors, particularly diet, influence cancer risk
by vitamin D pathway genotype.
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